The first AstraZeneca vaccine against Covid-19 returned to Vietnam today

This morning, right after arriving at Tan Son Nhat airport, completing customs clearance procedures, the batch of vaccines will be transported by specialized vehicles, with a strict preservation system as recommended by the manufacturer and imported. cold storage in Ho Chi Minh City.

According to the source, 117,600 doses of AstraZeneca's Covid-19 vaccine arrived at Tan Son Nhat airport, serving the current urgent need for epidemic prevention on February 24. This is the first Covid-19 vaccine licensed by the Ministry of Health and imported by Vietnam Vaccine Joint Stock Company (VNVC). This flight carrying the first batch of Covid-19 vaccine landed at Tan Son Nhat airport at 10:45 am on February 24. This is the first batch of 240,000-dose vaccines returned to Vietnam, approved for import by the Ministry of Health in February. The vaccine was facilitated by the Ministry of Health for emergency import in the context of Covid-19 infecting 13 provinces and cities. the past 27 days.

According to VNVC, the first batch of vaccines arrived earlier than originally planned, so the plan to deploy anti-epidemic vaccines for priority groups will also be implemented right in next March. The receipt of registration for Covid-19 vaccine from people injecting the service has been suspended, pending instructions from the Ministry of Health.

"VNVC has ready staff and facilities to serve up to 4 million doses of Covid-19 vaccine per month and ensure safe injections," said Mr. Bui Kim Khanh, Director of VNVC. nationwide VNVC system, said.

After the first batch of vaccines, in the first half of 2021, VNVC will bring to Vietnam 30 million doses of AstraZeneca's Covid-19 vaccine. Priority groups and people in the country will officially receive high-quality Covid-19 vaccines, as in Europe and many major countries around the world, contributing to controlling the pandemic.

AstraZeneca's vaccine was co-invented by the University of Oxford and the supporting manufacturing company Vaccitech. Vaccine using a viral vector that cannot replicate, created from an attenuated strain of common chimpanzee influenza virus (adenovirus), containing genetic material of the spike protein on the surface of the SARS-CoV-2 virus .

After vaccination, a spike surface protein is produced, triggering the immune system to attack the SARS-CoV-2 virus if the body is subsequently infected with the virus.

Published safety data from more than 20,000 participants in four clinical trials in the UK, Brazil and South Africa in The Lancet show that AstraZeneca's Covid-19 vaccine was well tolerated with no adverse events. serious benefit. Study participants were geographically and ethnically diverse, healthy or had stable underlying medical conditions.

At each negative cold storage, there is a defrost warehouse that is controlled at a temperature below 80 degrees Celsius to ensure that the vaccine is safely defrosted before being used. On February 1, the Ministry of Health officially granted a conditional license of AstraZeneca's Covid-19 vaccine for emergency cases of epidemic prevention and control.

On February 17, Mr. Le Viet Dung, Deputy Director of the Drug Administration of Vietnam, the Ministry of Health signed an official letter (No. 1215/QLD-KD) agreeing to let AstraZeneca Vietnam Co., Ltd. import 204,000 doses of vaccine.

On February 27, the Ministry of Health announced 11 groups of people to be vaccinated against Covid-19 first according to the priority of the epidemic situation and in the context of the current limited vaccine resources. In which, medical staff and staff involved in epidemic prevention (Steering Committees at all levels, staff of quarantine zones, reporters...) are given top priority.

The vaccine's protective efficacy ranges from 62-90%, depending on the dose administered. There were two different vaccine regimens in the trial. In regimen 1, volunteers received half the dose, then at least one month received the full dose, which was 90% effective. The second regimen, administered in two full doses one month apart, was 62% effective. The average efficiency of the two regimens was 70%.

ChAdOx is one of the vaccine candidates that has shown positive results in a large-scale phase 3 trial. Although not as effective as the products of two competitors, Moderna and Pfizer, in return, the Oxford vaccine is cheaper, easier to transport and store.

Sarah Gilbert - "Mẹ đẻ" vaccine AstraZeneca từ bỏ cơ hội kiếm hàng triệu USD để cứu thế giới là ai? Hoàng Phúc10:11:02 26/01/2022Vượt qua những khó khăn, thử thách trên con đường nghiên cứu khoa học, bà Sarah Gilbert cùng các cộng sự đã sáng chế thành công vaccine ngừa Covid-19 Oxford/Astrazeneca. Đây là một thành công và là niềm hy vọng lớn góp phần chấm dứt đại dịch. Suýt từ bỏ khoa học, sự...